Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cancer-Associated Fibroblast

Small molecule · developed by Gilead Sciences

Phase 4 Most advanced trial
GILD Developer
2 Registered trials

What is Cancer-Associated Fibroblast?

Cancer-Associated Fibroblast is an investigational small-molecule drug studied in HIV-1 Infection, HIV-1-infection.

At a glance

Drug type
Small molecule
Therapy area
Infectious disease
Developer
Gilead Sciences (GILD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06337032 Phase 4 HIV-1-infection Recruiting GILD
NCT02881320 Phase 2/3 HIV-1 Infection Active not recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV-1 Infection

More from Gilead Sciences

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Cancer-Associated Fibroblast

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.